drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous, gene-modified CAR T-cell therapy in which a patient’s T cells are transduced to express a CD19-directed KIR-based chimeric antigen receptor; upon binding CD19 on malignant B cells, the KIR-derived signaling domain activates the T cell to mediate cytokine release and cytotoxic killing of CD19+ cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express a CD19-directed KIR-based chimeric antigen receptor; binding to CD19 on malignant B cells triggers KIR-derived signaling that activates the T cells, inducing cytokine release and cytotoxic killing of CD19+ cells.
drug_name
SynKIR-310
nct_id_drug_ref
NCT06544265